RxDoctor Payments Data

David Nicholson, DO

Cardiovascular Disease · Gahanna, OHNPI 1083779466

Payments from drug & device makers

$27,811in general payments, 2019–2025

Across 117 payments — averaging $237.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$23K
  • Edwards Lifesciences$2K
  • Medtronic$792
  • Heartflow, Inc.$622
  • Abbott$362
  • Novo Nordisk$206
  • plus $647 from 14 others

What the payments were for

  • Consulting fees$1,5906%
  • Speaking & faculty fees$22,00079%
  • Food & beverage$4,09215%
  • Education$1300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,811 in reported general payments places this provider in the 80th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$122,565
Medicare patients
1,015
Services billed
1,866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban342$357,045
EntrestoSacubitril/Valsartan133$150,908
XareltoRivaroxaban84$79,237
FarxigaDapagliflozin Propanediol73$62,646
JardianceEmpagliflozin35$35,807
Repatha SureclickEvolocumab21$20,616
OzempicSemaglutide19$18,656
MounjaroTirzepatide15$15,535
MultaqDronedarone Hcl12$12,353
Repatha SyringeEvolocumab14$7,386
Metoprolol Succinate371$4,677
Ranolazine ErRanolazine42$3,958
Atorvastatin Calcium313$2,766
Flecainide Acetate32$2,617
Ezetimibe79$2,329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$33$150,908133 claims
Johnson & JohnsonXarelto$30$79,23784 claims
AstraZenecaFarxiga$61$62,64673 claims
Novo NordiskOzempic$206$18,65619 claims
Sanofi-aventis U.S. LLCMultaq$46$12,35312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Gahanna

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →